Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

BACKGROUND: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demon...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Cancer
Main Authors: Moon, Jai-Hee, Hong, Seung-Woo, Kim, Jeong Eun, Shin, Jae-Sik, Kim, Jin-Sun, Jung, Soo-A, Ha, Seung Hee, Lee, Seul, Kim, Joseph, Lee, Dae Hee, Park, Yoon Sun, Kim, Dong Min, Park, Sang-Soo, Hong, Jun Ki, Kim, Do Yeon, Kim, Eun Ho, Jung, Joonyee, Kim, Mi Jin, Kim, Seung-Mi, Deming, Dustin A., Kim, Kyunggon, Kim, Tae Won, Jin, Dong-Hoon
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://ncbi.nlm.nih.gov/pubmed/30944457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0434-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki